System Xc −/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy
FJ Li, HZ Long, ZW Zhou, HY Luo, SG Xu… - Frontiers in …, 2022 - frontiersin.org
The activation of ferroptosis is a new effective way to treat drug-resistant solid tumors.
Ferroptosis is an iron-mediated form of cell death caused by the accumulation of lipid …
Ferroptosis is an iron-mediated form of cell death caused by the accumulation of lipid …
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
J Feng, J Li, L Wu, Q Yu, J Ji, J Wu, W Dai… - Journal of Experimental & …, 2020 - Springer
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
W Tang, Z Chen, W Zhang, Y Cheng, B Zhang… - Signal transduction and …, 2020 - nature.com
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
Challenges in liver cancer and possible treatment approaches
Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …
Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic
properties, constitutes the only effective first-line drug approved for the treatment of …
properties, constitutes the only effective first-line drug approved for the treatment of …
[HTML][HTML] Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
FH Kong, QF Ye, XY Miao, X Liu, SQ Huang, L **ong… - Theranostics, 2021 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …
leading causes of cancer-related death worldwide. Advanced HCC displays strong …
Mechanisms of drug resistance in HCC
HCC comprises∼ 80% of primary liver cancer. HCC is the only major cancer for which death
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …
rates have not improved over the last 10 years. Most patients are diagnosed with advanced …
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
S Chen, Q Cao, W Wen, H Wang - Cancer letters, 2019 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which
ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy …
ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy …